ERBB2 and breast carcinoma: In light of the findings of our study, we can conclude that the resistance to anti-HER2 therapies in HER2-positive breast cancer is closely associated with alterations in metabolic reprogramming, protein turnover, and the CDK-Rb-E2F pathway.